Roche’s Teresa Graham says patients are clamoring for breast cancer pill giredestrant as two US approval decisions near.
Arbutus' AB-101 hold lifted; GSK drops HBV drug; Ultomiris approved for IgAN; Biohaven resubmits SCA app; Arcus raises $250M; ...
AbbVie’s IL-1α and IL-1β inhibitor lutikizumab improved patient response rates after 16 weeks by a statistically significant ...
Sanofi breaks ground on a Frankfurt insulin plant, FDA warns Baxter over cephalosporin contamination, and radiopharma players ...
FDA weighs evidence standards for AI medical devices like prescription bots. AMA opposes upfront uncertainty; ATA Action supports post-market monitoring. UpDoc, AMA, and others back risk-based ...
Redesign Health merges with Sheba Medical Center’s ARC Global in a roughly $2B deal and plans to acquire advisory firm AVIA.
Roche touts 88% Phase 3 success rate as it culls afimkibart’s AD trial and seven early assets ahead of giredestrant launch.
Rezera (formerly NodThera) filed for Nasdaq IPO as $RZRA, targeting Phase 3 for PAD in 2027 with NLRP3 inhibitor ruvonoflast. Novo Holdings and Blue Owl Capital each own 24%.
Pharma braces for a tougher Treasury scrutiny of China deals as draft outbound investment rules are expected Thursday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results